injection de semaglutide Tirzepatide vs Transitioning From MDI Insulin to

Protein intake is crucial in keeping your body healthy and energized

Manufactured in GMP, FDA, and WHO-certified facility

Dosing Protocol Key Efficacy Data The SURMOUNT clinical trial program established tirzepatide as the most effective GLP-1 weight loss agent currently available: SURMOUNT-1 (adults without diabetes): Mean weight loss of 20.9% (10 mg), 24.0% (15 mg) at 72 weeks versus 3.1% placebo (Jastreboff et al., NEJM , 2022) SURMOUNT-2 (adults with type 2 diabetes): Mean weight loss of 12.8% (10 mg), 14.7% (15 mg) at 72 weeks (Garvey et al., Lancet , 2023) SURMOUNT-3 (after intensive lifestyle intervention lead-in): Mean total weight loss of 26.6% with tirzepatide 15 mg (Wadden et al., Nature Medicine , 2023) SURMOUNT-4 (withdrawal study): Patients who discontinued tirzepatide after 36 weeks regained approximately two-thirds of lost weight by week 88, demonstrating the chronic disease nature of obesity and the need for ongoing treatment (Aronne et al., JAMA , 2024) Why Dual Agonism Matters The GIP receptor activation in tirzepatide produces additive effects beyond GLP-1 agonism alone

In simple terms, one is a defensive reaction to external damage, while the other is a direct biochemical stimulation of pigment cells